| Literature DB >> 30881993 |
Zhiyong Dong1, Wei Lin2, Stacy A Kujawa3, Shike Wu4, Cunchuan Wang1.
Abstract
BACKGROUND: Colon cancer is a heterogeneous disease, differing in clinical symptoms, epigenetics, and prognosis for each individual patient. Identifying the core genes is important for early diagnoses and it provides a more precise method for treating colon cancer.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30881993 PMCID: PMC6383401 DOI: 10.1155/2019/6341967
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The characteristics of patients' tissue information in GSE101502.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Cancer group | GSM2705118 | Patient 1 | Primary colon cancer | TNM:IIA | alive | 62 | male | Cancer tissue |
| GSM2705119 | Patient 2 | Primary colon cancer | TNM:IIA | alive | 62 | male | Cancer tissue | |
| GSM2705120 | Patient 3 | Primary colon cancer | TNM:IIA | alive | 64 | male | Cancer tissue | |
| Normal group | GSM2705121 | Patient 4 | Primary colon cancer | TNM:IIA | alive | 62 | male | Adjacent normal mucosa |
| GSM2705122 | Patient 5 | Primary colon cancer | TNM:IIA | alive | 62 | male | Adjacent normal mucosa | |
| GSM2705123 | Patient 6 | Primary colon cancer | TNM:IIA | alive | 64 | male | Adjacent normal mucosa |
Identification of differentially expressed miRNA.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| 1 | hsa-miR-5195-3p | 0.863 | 0.00755 | 3.480604 | -4.53 | 2.143968 |
| 2 | hsa-miR-548aw | 0.863 | 0.04462 | 2.481081 | -4.58 | 2.063515 |
| 3 | hsa-miR-5681a | 0.863 | 0.02794 | -2.816049 | -4.57 | -2.112315 |
| 4 | hsa-miR-561-3p | 0.863 | 0.04632 | -2.559382 | -4.58 | -2.141209 |
| 5 | hsa-miR-4777-3p | 0.863 | 0.01428 | -3.314158 | -4.56 | -2.160746 |
| 6 | hsa-miR-500a-3p | 0.863 | 0.03301 | -2.541129 | -4.55 | -2.226463 |
| 7 | hsa-miR-29c-3p | 0.863 | 0.03073 | -2.585747 | -4.55 | -2.232961 |
| 8 | hsa-miR-200a-3p | 0.863 | 0.03114 | -2.577578 | -4.55 | -2.279405 |
| 9 | hsa-miR-34c-3p | 0.863 | 0.01521 | -3.028324 | -4.54 | -2.305722 |
| 10 | hsa-miR-378d | 0.863 | 0.03592 | -2.488453 | -4.56 | -2.354464 |
| 11 | hsa-miR-142-3p | 0.863 | 0.03736 | -2.463817 | -4.56 | -2.488274 |
| 12 | hsa-miR-4524b-3p | 0.863 | 0.02313 | -3.116108 | -4.58 | -2.565208 |
| 13 | hsa-miR-3653-3p | 0.863 | 0.01347 | -3.105707 | -4.54 | -2.832038 |
| 14 | hsa-miR-320c | 0.863 | 0.00898 | -3.367253 | -4.54 | -2.926313 |
| 15 | hsa-miR-375 | 0.863 | 0.00836 | -3.413574 | -4.54 | -3.17402 |
| 16 | hsa-miR-4539 | 0.863 | 0.02251 | -2.780929 | -4.55 | -3.278709 |
| 17 | hsa-miR-215-5p | 0.863 | 0.01006 | -3.293314 | -4.54 | -3.955771 |
GO analysis of differentially expressed genes associated with IIA stage colon cancer.
|
|
|
|
| % |
|
|
|
|---|---|---|---|---|---|---|---|
| up | GOTERM_BP_FAT | GO:0010646~regulation of cell communication | 234 | 24.92013 | 2.36E-12 | 1.526744778 | 4.63E-09 |
| up | GOTERM_BP_FAT | GO:0023051~regulation of signaling | 236 | 25.13312 | 4.03E-12 | 1.514715803 | 7.91E-09 |
| up | GOTERM_BP_FAT | GO:0007399~nervous system development | 180 | 19.16933 | 8.89E-12 | 1.63444496 | 1.75E-08 |
| up | GOTERM_BP_FAT | GO:0010604~positive regulation of macromolecule metabolic process | 220 | 23.42918 | 2.72E-11 | 1.517826065 | 5.34E-08 |
| up | GOTERM_BP_FAT | GO:0007167~enzyme linked receptor protein signaling pathway | 98 | 10.43663 | 2.73E-11 | 2.024115217 | 5.37E-08 |
| up | GOTERM_MF_FAT | GO:0005057~receptor signaling protein activity | 27 | 2.875399 | 2.69E-08 | 3.580476019 | 4.39E-05 |
| up | GOTERM_MF_FAT | GO:0000982~transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding | 41 | 4.366347 | 1.00E-06 | 2.33015106 | 0.001631 |
| up | GOTERM_MF_FAT | GO:0019899~enzyme binding | 136 | 14.48349 | 1.81E-06 | 1.481913682 | 0.002953 |
| up | GOTERM_MF_FAT | GO:0008092~cytoskeletal protein binding | 75 | 7.98722 | 3.96E-06 | 1.728165139 | 0.006455 |
| up | GOTERM_MF_FAT | GO:0019904~protein domain specific binding | 59 | 6.28328 | 4.69E-06 | 1.873173393 | 0.00764 |
| up | GOTERM_CC_FAT | GO:0030054~cell junction | 123 | 13.09904 | 2.20E-09 | 1.711673403 | 3.35E-06 |
| up | GOTERM_CC_FAT | GO:0031252~cell leading edge | 44 | 4.685836 | 2.05E-07 | 2.378506707 | 3.12E-04 |
| up | GOTERM_CC_FAT | GO:0005912~adherens junction | 69 | 7.348243 | 3.11E-07 | 1.907961809 | 4.74E-04 |
| up | GOTERM_CC_FAT | GO:0070161~anchoring junction | 69 | 7.348243 | 7.57E-07 | 1.862342469 | 0.001153 |
| down | GOTERM_BP_FAT | GO:0007399~nervous system development | 546 | 18.8601 | 3.19E-36 | 1.619387 | 6.50E-33 |
| down | GOTERM_BP_FAT | GO:0006357~regulation of transcription from RNA polymerase II promoter | 468 | 16.1658 | 4.34E-32 | 1.64145 | 8.83E-29 |
| down | GOTERM_BP_FAT | GO:0051254~positive regulation of RNA metabolic process | 375 | 12.95337 | 7.66E-29 | 1.705661 | 1.56E-25 |
| down | GOTERM_BP_FAT | GO:0006366~transcription from RNA polymerase II promoter | 453 | 15.64767 | 1.98E-28 | 1.601934 | 4.03E-25 |
| down | GOTERM_BP_FAT | GO:1903508~positive regulation of nucleic acid-templated transcription | 360 | 12.43523 | 2.90E-28 | 1.717546 | 5.91E-25 |
| down | GOTERM_MF_FAT | GO:0000981~RNA polymerase II transcription factor activity, sequence-specific DNA binding | 188 | 6.493955 | 3.54E-17 | 1.799249 | 6.12E-14 |
| down | GOTERM_MF_FAT | GO:0001067~regulatory region nucleic acid binding | 225 | 7.772021 | 7.28E-16 | 1.663386 | 1.34E-12 |
| down | GOTERM_MF_FAT | GO:0000975~regulatory region DNA binding | 224 | 7.737478 | 1.35E-15 | 1.657928 | 2.31E-12 |
| down | GOTERM_MF_FAT | GO:0044212~transcription regulatory region DNA binding | 223 | 7.702936 | 1.78E-15 | 1.656331 | 3.08E-12 |
| down | GOTERM_MF_FAT | GO:0043565~sequence-specific DNA binding | 267 | 9.222798 | 3.59E-15 | 1.566314 | 6.15E-12 |
| down | GOTERM_CC_FAT | GO:0005654~nucleoplasm | 632 | 21.83074 | 2.75E-18 | 1.331786 | 4.42E-15 |
| down | GOTERM_CC_FAT | GO:0043005~neuron projection | 233 | 8.048359 | 5.31E-12 | 1.522783 | 8.54E-09 |
| down | GOTERM_CC_FAT | GO:0097458~neuron part | 297 | 10.25907 | 8.60E-11 | 1.406649 | 1.38E-07 |
| down | GOTERM_CC_FAT | GO:0098644~complex of collagen trimers | 18 | 0.621762 | 9.04E-10 | 4.940876 | 1.45E-06 |
KEGG pathway analysis of target genes associated with IIA stage colon cancer.
| Regulated | Category | Term | Count | % | P-Value | Fold Enrichment | FDR |
|---|---|---|---|---|---|---|---|
| Up | KEGG_PATHWAY | hsa04360:Axon guidance | 21 | 2.24 | 7.30E-06 | 3.173885 | 0.009462 |
| Up | KEGG_PATHWAY | hsa04010:MAPK signaling pathway | 31 | 3.30 | 1.94E-05 | 2.333442 | 0.025073 |
| Up | KEGG_PATHWAY | hsa04144:Endocytosis | 31 | 3.30 | 2.43E-05 | 2.306309 | 0.031476 |
| Up | KEGG_PATHWAY | hsa05205:Proteoglycans in cancer | 26 | 2.77 | 3.53E-05 | 2.495278 | 0.045696 |
| Up | KEGG_PATHWAY | hsa04068:FoxO signaling pathway | 20 | 2.13 | 5.61E-05 | 2.864842 | 0.072721 |
| Down | KEGG_PATHWAY | hsa05200:Pathways in cancer | 108 | 3.73 | 1.58E-10 | 1.810230026 | 2.10E-07 |
| Down | KEGG_PATHWAY | hsa04510:Focal adhesion | 66 | 2.28 | 1.44E-09 | 2.110470443 | 1.90E-06 |
| Down | KEGG_PATHWAY | hsa04151:PI3K-Akt signaling pathway | 91 | 3.14 | 4.76E-08 | 1.737500173 | 6.31E-05 |
| Down | KEGG_PATHWAY | hsa05222:Small cell lung cancer | 32 | 1.11 | 9.87E-07 | 2.479896821 | 0.001306893 |
| Down | KEGG_PATHWAY | hsa04550:Signaling pathways regulating pluripotency of stem cells | 44 | 1.52 | 2.04E-06 | 2.070271006 | 0.002694908 |
Figure 1All target genes were screened and shown as association networks by STRING.
Figure 2Top 4 modules from the PPI network. (a, c, e, g) modules 1 to 4; (b, d, f, h) the enriched pathway of modules 1 to 4.
Figure 3Prognostic values of the four genes (NUDT21, GNB1, CLINT1, and COL1A2) in colon cancer patients. Overall survival analysis over time with high vs. low NUDT2 expression (a), low vs. high COL1A2 expression (b), high vs. low GNB1 expression (c), and low vs. high CLINT1 expression (d). The P value was determined by log-rank test between risk groups.
Figure 4Expression levels of the four genes: NUDT21 (a), GNB1 (b), CLINT1 (c), and COL1A2 (d) in colon cancer and normal tissues. ∗P < 0.05.